OIG Report on Supplement Claims Finds Disease Claims, Substantiation Issues

The HHS Office of the Inspector General finds a number of issues with supplement structure/function claims, and makes several recommendations to FDA to reduce illegal claims and weak substantiation.

FDA will seek out additional opportunities to enforce dietary supplement structure/function regulations, with disease claims still the priority, the agency says in response to a government investigation that found 20% of 127 weight-loss and immune support supplement products it reviewed carried disease claims.

The Office of the Inspector General in the Department of Health and Human Services conducted the investigation and published a...

More from United States

More from North America

How Could MFN Pricing Impact Commercial Market?

 
• By 

Industry experts forecast the impact of President Trump's Most-Favored Nation drug pricing policy on the commercial insurance industry.

COVID-19 mRNA Vaccine Labels Now Quantify Myocarditis Risk, But ACIP Wants Other Changes

 
• By 

New members of the CDC’s Advisory Committee on Immunization Practices suggested concerns beyond myocarditis, questioning whether test-negative observational studies are giving an incorrect picture of effectiveness.

Medicare’s Combo Products Negotiation Plan Conflicts With US FDA Standards, Firms Argue

 
• By 

The plan could curtail a period of pricing flexibility for newer subcutaneous versions of important oncology drugs.